© Foto: © 2023 Merck & Co
Realtime | Geld | Brief | Zeit |
---|---|---|---|
119,80 | 120,80 | 11.05. | |
120,40 | 121,00 | 10.05. |
© Foto: © 2023 Merck & Co
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Fr | MSD's maternal health initiative passes big milestone | ||
Do | Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer | ||
Do | Merck's Phase 3 Trial Of KEYTRUDA Plus Chemotherapy In Endometrial Cancer Fails To Meet Primary Goal | KENILWORTH (NJ) (dpa-AFX) - Drug major Merck & Co., Inc. (MRK) announced Thursday that the Phase 3 KEYNOTE-B21 trial evaluating its anti-PD-1 therapy KEYTRUDA (pembrolizumab), in combination... ► Artikel lesen | |
Do | Merck & Co verfehlt Studienziel bei Blockbuster-Krebsmedikament | ||
Do | Merck' Keytruda Receives Approval From Health Canada For Biliary Tract Carcinoma In Adults | KENILWORTH (NJ) (dpa-AFX) - Thursday, Merck & Co., Inc. (MRK) announced that Health Canada has approved Keytruda, also known as pembrolizumab, for the treatment of adult patients with locally... ► Artikel lesen |